Defining the Epidemiologic Scope of Cardio-Kidney-Metabolic Syndrome

The Texas Heart Institute

A. Pandey

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Social Determinants of Health for Cardiovascular Kidney Metabolic Sy…

Kibret Enyew Belay

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

State-of-the-Art, Treatment of Diabetic Kidney Disease (DKD)

Primary Care Education Consortium

S. Brunton

Current Status of Prevention and Treatment of Diabetic Nephropathy

George Bakris

Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

The Texas Heart Institute

G. Bakris

What's the Ideal Therapy for Obesity?

Stanford Medicine

A. Yeoh

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

ACC 2024 Insights

M. Costanzo

SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus

Javed Butler

Diabetes and Heart Failure: The New Frontier

Mount Sinai Advanced Innovations in Heart Failure Symposium 2019

E. Braunwald

Year in Review - Obesity and Cardiovascular Kidney Syndrome: New Goa…

Samina Yunus

What the Guidelines Tell Us About Cardiometabolic Syndrome

The Texas Heart Institute

S. Virani

Updates in Nephrology

University of Colorado Department of Medicine

A. Jovanovich

Diabetes Management in CKD: KDIGO 2022 Clinical Practice Update

Cleveland Clinic Endocrinology & Metabolism Institute

L. Caramori

Hyperkalemia in Chronic Kidney Disease

George Bakris

Management of Kidney Health in CKD and DKD: A Cased-Based Multiple-c…

Bijin Thajudeen

Updates on ADA Standards of Care - 2022

Scripps Health

A. Tsimikas, L. Vincent